...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors
【24h】

Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors

机译：两种肺癌血糖淋巴管癌免疫检查点抑制剂引起的病例

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We report the cases of two patients with secondary hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors, who were diagnosed using the recently developed HScore. The first patient presented with fever, cytopenia, and elevated liver enzyme levels at 46?days post‐pembrolizumab administration. The HScore was 175. The second patient developed an immune‐related adverse event at 30?days after the final pembrolizumab dose. The HScore was 185. Hemophagocytic lymphohistiocytosis was confirmed in both patients, and corticotherapy improved their condition. It is challenging to diagnose hemophagocytic lymphohistiocytosis, particularly after development at a late stage. Our patients developed hemophagocytic lymphohistiocytosis late after immune checkpoint inhibitor administration. However, the HScore enabled us to diagnose both cases precisely and in a timely manner.
机译：我们报道了两种患有免疫检查点抑制剂引起的二次血液淋巴细胞增多症患者的病例，该抑制剂是使用最近开发的HSCORE诊断的。 第一个患者患有发烧，细胞脑，肝脏酶水平升高，在Pembrolizumab管理后46℃。 HSCORE是175.第二患者在最终PEMBROLIZUMAB剂量后30次出现免疫相关的不良事件。 HSCORE是185.患者在两种患者中证实了血糖淋巴管菌，并且皮质疗法改善了它们的病症。 诊断血糖淋巴管激菌症有挑战性，特别是在晚期发育后的发育后。 我们的患者在免疫检查点抑制剂给药后晚期出现血糖淋巴管激菌症。 但是，HSCORE使我们能够精确地诊断两种情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号